1Geller DS, Gorliek R. Osteosarcoma, a review of diagnosis, man- agement,and treatment strategies [J]. Clin Adv Hematol Oncol, 2010,8(10) :705.
2Shin SH,Jeong HJ, Han I,et al. Osteosarcoma and chondrosarco ma of the shoulder: site-specific comparative analysis[J]. Orthope- dics, 2013,36(2) : 179.
3Bacci G,Briccoli A,Ferrari S,et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol[J]. Eur J Cancer,2001,37(16) :2030.
4Vesprini D, Liu S,Nam R. Predicting high risk disease using serum and DNA biomarkers[J]. Curt Opin Urol,2013,23(3) :252.
5Heo CK, Bahk YY, Cho EW. Tumor-associated autoantibodies as diagnostic and prognostic biomarkers [J]. BMB Rep, 2012, 45 (12) 677.
6Savitskaya YA, Rico-Martinez G, Linares-Gonzdlez LM, et al. Ser- um tumor markers in pediatric osteosarcoma: a summary review [J]. Clin Sarcoma Res,2012,23(2) :9.
7Wittmann J ,Jack HM. Serum microRNAs as powerful cancer bio- rnarkers[J]. Bioehim Biophys Acta, 2010,1806(2) : 200.
8Zhang Z, Qiu Y, Hua Y, et al. Serum and urinary metabonomic study of human osteosarcoma [J]. J Proteome Res, 2010,9 (9) : 4861.
9Oliveira ID, Petrilli AS, Tavela MH, et al. TNF-alpha,TNF-beta, IL 6,IL-10,PECAM 1 and the MPO inflammatory gene polymorphisms in osteosarcoma [J]. J Pediatr Hematol Oncol, 2007,29 (5) 293.
10Holzer G, PfancIlsteiner T, Blahovec H, et al. Serum levels of TNF-beta and sTNF R in patients with malignant bone tumours [J]. Anticancer Res. 2003,23(3C) :3057.
